Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Merck
Moodys
Express Scripts
Mallinckrodt

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

EXUBERA Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Exubera patents expire, and what generic alternatives are available?

Exubera is a drug marketed by Pfizer and is included in one NDA. There are three patents protecting this drug.

This drug has three hundred and thirty-four patent family members in fifty-eight countries.

The generic ingredient in EXUBERA is insulin recombinant human. There are forty drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the insulin recombinant human profile page.

Summary for EXUBERA
International Patents:334
US Patents:3
Applicants:1
NDAs:1
Bulk Api Vendors: 1
Clinical Trials: 25
Formulation / Manufacturing:see details
DailyMed Link:EXUBERA at DailyMed
Drug patent expirations by year for EXUBERA
Recent Clinical Trials for EXUBERA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Mannkind CorporationPhase 3
PfizerN/A
Mannkind CorporationPhase 2

See all EXUBERA clinical trials

Synonyms for EXUBERA
11081-38-2
37243-75-7
37294-43-2
57126-42-8
69090-47-7
8049-67-0
8049-95-4
88026-11-3
88026-12-4
9004-10-8
9045-63-0
9045-65-2
9045-66-3
9045-67-4
9066-39-1
9066-40-4
AERx
AERx [Insulin management system]
CCRIS 5464
CHEBI:5931
Dal-insulinum
Decurvon
Dermulin
EINECS 232-672-8
Endopancrine
HMR 4006
HSDB 3102
Humilin
Iletin
Imusay-131
Injectable insulini neutrale
Insular
insulin (recombinant)
INSULIN INJECTION
Insulin recombinant
insulin-human
Insulin, dalanated
Insulin, dalanated [USAN:INN]
Insulina dalanatada
Insulina dalanatada [INN-Spanish]
Insulina iniettabile neutra
Insulina iniettabile neutra [DCIT]
Insulini injectio neutralis
Insulini injectio neutralis [INN-Latin]
Insulinum dalanatum
Insulinum dalanatum [INN-Latin]
Insulyl
Intesulin B
Inyectable neutro de insulina
Inyectable neutro de insulina [INN-Spanish]
Iszilin
Musulin
S.N. 44
Solute neutre injectable d'insuline
Solute neutre injectable d'insuline [INN-French]

US Patents and Regulatory Information for EXUBERA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer EXUBERA insulin recombinant human POWDER;INHALATION 021868-001 Jan 27, 2006 DISCN No No   Start Trial   Start Trial Y   Start Trial
Pfizer EXUBERA insulin recombinant human POWDER;INHALATION 021868-002 Jan 27, 2006 DISCN No No   Start Trial   Start Trial Y   Start Trial
Pfizer EXUBERA insulin recombinant human POWDER;INHALATION 021868-001 Jan 27, 2006 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for EXUBERA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer EXUBERA insulin recombinant human POWDER;INHALATION 021868-002 Jan 27, 2006   Start Trial   Start Trial
Pfizer EXUBERA insulin recombinant human POWDER;INHALATION 021868-002 Jan 27, 2006   Start Trial   Start Trial
Pfizer EXUBERA insulin recombinant human POWDER;INHALATION 021868-002 Jan 27, 2006   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Premature patent expiration for: EXUBERA

Expiration due to failure to pay maintenance fee

Patent Number Tradename Expiration Date
  Start Trial EXUBERA   Start Trial

Supplementary Protection Certificates for EXUBERA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2498802 122017000039 Germany   Start Trial PRODUCT NAME: SULIQUA (FIRMENEIGENER NAME DES MEDIZINISCHEN PRODUKTS) BZW. WIRKSTOFFZUSAMMENSETZUNG UMFASSEND INSULIN GLARGIN / LIXISENATID UND IHRE PHARMAZEUTISCH ANNEHMBAREN SALZE (INTERNATIONALER, NICHT FIRMENEIGENER NAME); REGISTRATION NO/DATE: EU/1/16/1157 20170111
2107069 92226 Luxembourg   Start Trial PRODUCT NAME: COMBINATION D'INSULINE DEGLUDEC ET INSULINE ASPARTE SOUS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; FIRST REGISTRATION DATE: 20130121
2597103 19/2017 Austria   Start Trial PRODUCT NAME: KOMBINATION VON INSULIN DEGLUTEC UND LIRAGLUTID; NAT. REGISTRATION NO/DATE: EU/1/14/947/001-4 20140918; FIRST REGISTRATION: LI 65041 (CH) 20140912
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
AstraZeneca
McKinsey
Baxter
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.